In this interview, Jun Qu (University at Buffalo; NY, USA) describes his current research focuses, including the technologies he is currently developing. Jun goes on to discuss the challenges involved in implementing sensitive quantifications of biotherapeutics using LC–MS and speculates on the future of the technology.
Learn about new UHPLC column technologies and how to exploit them for improved characterization of biomacromolecules in our free upcoming webinar!
LC-MS-based approaches are increasingly used for the quantification of proteins in biological samples. Traditionally, triple…
Wacker Biotech GmbH (Jena, Germany) have announced that they will manufacture the active ingredient in the drug Retavase®. This drug has obtained FDA approval to treat acute myocardial infarction in adults.
The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
12. How do you see the field evolving over the next 5-10 years? What are the main obstacles to be overcome?
In our final instalement, our experts look towards the future and comment on how they see the field evolving over the next 5-10 years.
Available to view on demand: In this webinar, Glenn Petrie discusses best practice in optimizing the Chemistry, Manufacturing and Control (CMC) process.